K-Pharmaceutical Bio proves ‘food for the future’ with statistics

[팜뉴스=최선재 기자] The Korean biopharmaceutical industry is proving the growth of the industry through statistics. It was found that the scale of the industry is growing, and corporate investment and innovation are continuing in various fields such as exports, R&D, clinical trials, and jobs.

According to the ‘2021 Pharmaceutical Bio Industry Data Book’ published by the Korea Pharmaceutical and Biotechnology Association (Chairman Won Hee-mok) on the 10th, the total production amount of pharmaceuticals, etc. (finished drugs + raw materials + quasi-drugs) in the pharmaceutical industry in 2020 is 28,28.4 billion won, 5 years ago (20,548.7 billion won in 2016), an increase of 36.4%. The share of the manufacturing sector in terms of GDP jumped from 4.1% in 2016 to 5.8% last year.

Pharmaceutical exports, which stood at 3.62 trillion won in 2016, expanded to 9.96 trillion won in 2020, close to 10 trillion won. As a result, Korean pharmaceuticals achieved a trade surplus for the first time in history in 2020.

Job creation continues. The number of workers in the pharmaceutical and bio industry exceeded 100,000 for the first time in 2019, and in 2020, the number was 114,126, an increase of 10,000 from the previous year.

In 2020, the total R&D expenditure of the pharmaceutical and bio industry was KRW 2.1 trillion, an increase of 21.3% compared to the previous year (KRW 1.805.7 trillion). The proportion of R&D as a percentage of total sales in the pharmaceutical and bio industry was 6.5%, more than double the manufacturing average (2.6%). In addition, 12.3% of listed pharmaceutical companies and 14.2% of innovative pharmaceutical companies were surveyed.

Clinical trials also showed growth. The number of clinical trial approvals for synthetic drugs increased from 387 (2016) to 485 (2020), an increase of nearly 100. The number of biopharmaceuticals increased from 226 (2016) to 291 (2020). By region, overseas clinical trials were more active than domestic clinical trials. The number of domestic clinical trials increased from 190 (2016) to 256 (2020), and multinational clinical trials ranged from 267 to 355 during the same period.

On the other hand, the pharmaceutical bio industry data book published by the association every year can be obtained from the KPBMA data room and periodicals category on the official website.


Leave a Reply

Your email address will not be published. Required fields are marked *